Online Program Home
My Program

Abstract Details

Activity Number: 397
Type: Invited
Date/Time: Tuesday, August 2, 2016 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #318471
Title: The Statisticians Role as a Strategic Drug Developer in Rare Disease Indications
Author(s): Jeff Palmer*
Companies: Pfizer
Keywords: Historical ; Bayesian ; Composite ; Accelerated
Abstract:

In many rare disease indications the optimal clinical development option is to employ an accelerated approach (accelerated approval, fast-track, priority, and breakthrough designation). Innovative statistical (and non-statistical) methods must be used to address these non-standard approaches in drug development. Statisticians therefore must be an integral part of the strategy behind clinical development planning. In this talk I will present and discuss examples where creative statistical methods have been used to support accelerated approval for diseases with substantial unmet medical need; including the use of historical control data, Bayesian analyses, and unique composite endpoints that may be more sensitive to detecting a treatment effect.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association